- Trials with a EudraCT protocol (270)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (25)
270 result(s) found for: Amylase.
Displaying page 9 of 14.
EudraCT Number: 2012-003654-86 | Sponsor Protocol Number: GLPG0634-CL-204 | Start Date*: 2013-08-15 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled, multicenter, phase IIb dose finding study of GLPG0634 administered for 24 weeks as monotherapy to subjects with moderately to severely active rheumatoi... | |||||||||||||
Medical condition: moderately to severely active rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) AT (Completed) ES (Completed) LV (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002992-33 | Sponsor Protocol Number: E7080-G000-304 | Start Date*: 2013-07-04 | |||||||||||
Sponsor Name:Eisai Limited | |||||||||||||
Full Title: A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular... | |||||||||||||
Medical condition: Unresectable Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) PL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012787-14 | Sponsor Protocol Number: BAY73-4506/14387 | Start Date*: 2010-05-10 | ||||||||||||||||||||||||||
Sponsor Name:Bayer HealthCare AG | ||||||||||||||||||||||||||||
Full Title: A randomized, double-blind, placebo-controlled phase III study of regorafenib plus BSC versus placebo plus BSC in patients with metastatic colorectal cancer (CRC) who have progressed after standar... | ||||||||||||||||||||||||||||
Medical condition: Metastatic Colorectal Carcinoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) HU (Completed) PT (Completed) ES (Completed) CZ (Completed) IT (Completed) FR (Completed) NL (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-003418-32 | Sponsor Protocol Number: GS-US-104-0352 | Start Date*: 2007-12-18 | |||||||||||
Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
Full Title: A Phase III, Randomised, Open- Label Study Comparing the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate versus Continuing Stavudine or Zidovudine in Virol... | |||||||||||||
Medical condition: HIV-1 infected children (2 years to less than 12 years), who are virologically suppressed with HIV-1 RNA less than 400 copies/mL on their current antiretroviral regimen. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000357-35 | Sponsor Protocol Number: CAMN107DDE05 | Start Date*: 2008-11-04 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: An open-label, multi-center study to evaluate the efficacy of nilotinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and sunitinib | |||||||||||||
Medical condition: metastatic or unresectable gastrointestinal stromal tumor in patients resistant to imatinib or sunitinib | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000241-39 | Sponsor Protocol Number: BAY86-9766/16728 | Start Date*: 2013-07-26 |
Sponsor Name:Bayer HealthCare AG | ||
Full Title: A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in combination with sorafenib as first line treatment in patients with RAS mutant Hepato... | ||
Medical condition: KRAS or NRAS mutant unresectable or metastatic Hepatocellular carcinoma (HCC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) CZ (Completed) GB (Completed) DE (Completed) BE (Completed) IT (Completed) HU (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-000171-41 | Sponsor Protocol Number: 0000726 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Altus Pharmaceuticals Inc | |||||||||||||
Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insuff... | |||||||||||||
Medical condition: Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) IT (Completed) SK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023178-37 | Sponsor Protocol Number: GS-US-264-0106 | Start Date*: 2011-02-04 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/... | |||||||||||||
Medical condition: Human Immunodeficiency Virus (Type 1) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) ES (Completed) BE (Completed) IT (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000408-24 | Sponsor Protocol Number: D5551C00002 | Start Date*: 2016-04-13 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study to Assess the Safety and Efficacy of Exenatide Once Weekly in Adolescents with Type 2 Diabetes | |||||||||||||
Medical condition: Type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000709-59 | Sponsor Protocol Number: LCCC1029 | Start Date*: 2012-06-07 | |||||||||||
Sponsor Name:The Irish Clinical Oncology Research Group | |||||||||||||
Full Title: A Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) Versus Placebo With FOLFIRI as Second-Line Ther... | |||||||||||||
Medical condition: Second-Line Therapy in Patients with Metastatic Colorectal Cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001546-34 | Sponsor Protocol Number: EADO_VC_NEO_1 | Start Date*: 2014-10-02 | ||||||||||||||||
Sponsor Name:University Hospital Tübingen | ||||||||||||||||||
Full Title: Neoadjuvant treatment with the combination of Vemurafenib, Cobimetinib and Atezolizumab in limited metastasis of malignant melanoma (AJCC stage IIIC/IV) and integrated biomarker study: A single arm... | ||||||||||||||||||
Medical condition: Patients with hardly resectable/unresectable limited metastasis in malignant melanoma stages IIIC/IV (American Joint Committee on Cancer (AJCC) 2010) carrying the BRAF V600 mutation, in order to ac... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-024262-22 | Sponsor Protocol Number: CML-V | Start Date*: 2012-08-24 | |||||||||||
Sponsor Name:Friedrich-Schiller-Universität Jena | |||||||||||||
Full Title: Treatment optimization of newly diagnosed Ph/BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase with nilotinib vs. nilotinib plus interferon alpha induction and nilotini... | |||||||||||||
Medical condition: chronic phase CML | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003634-93 | Sponsor Protocol Number: NLG2107 | Start Date*: 2018-02-28 |
Sponsor Name:NewLink Genetics Corporation | ||
Full Title: A Phase 2/3 (Adaptive Design) Study of the Concomitant Administration of Indoximod or Placebo plus Pembrolizumab or Nivolumab in Adult Patients with Unresectable Stage III or Stage IV Malignant Mel... | ||
Medical condition: Adult Patients with Unresectable Stage III or Stage IV Malignant Melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001381-96 | Sponsor Protocol Number: LG_T1_EGP | Start Date*: 2014-06-17 |
Sponsor Name:Medizinische Universität Graz / Endokrinologie und Stoffwechsel | ||
Full Title: A randomized, double blind, two-period cross-over trial investigating the effect of liraglutide as add on to intensive insulin treatment on the endogenous glucose production in subjects with C-pept... | ||
Medical condition: Diabetes Mellitus Type 1 | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-005008-14 | Sponsor Protocol Number: GLPG0634-CL-202 | Start Date*: 2012-05-10 | |||||||||||
Sponsor Name:Galapagos SASU | |||||||||||||
Full Title: Randomized, Double blind, Placebo-controlled, Multicenter, Phase II Study to Compare Four Dose Regimens of GLPG0634 Versus Placebo, in Combination With Methotrexate, Administered for 4 Weeks in the... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003716-12 | Sponsor Protocol Number: C34004 | Start Date*: 2017-07-18 | |||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited | |||||||||||||
Full Title: Phase 2 Study of TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After at Least 2 Prior Lines of Chemotherapy | |||||||||||||
Medical condition: Relapsed or Refractory Diffuse Large B-Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Prematurely Ended) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004285-53 | Sponsor Protocol Number: VA 2008/28 | Start Date*: 2008-12-19 | |||||||||||
Sponsor Name:Centre Régional de Lutte contre le Cancer Val d'Aurelle- Paul Lamarque | |||||||||||||
Full Title: Etude de phase I-II évaluant l’association Sorafénib (NEXAVAR®) et Irinotecan en deuxième ligne ou plus de traitement des cancers colorectaux métastatiques avec une mutation de Kras – NEXIRI | |||||||||||||
Medical condition: Cancer du côlon ou du rectum métastatique prouvé histologiquement | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004137-91 | Sponsor Protocol Number: Gesida92016 | Start Date*: 2018-01-23 | |||||||||||
Sponsor Name:Fundacion SEIMC-GESIDA | |||||||||||||
Full Title: A single-arm, open-label, multicenter phase IV trial to evaluate the efficacy and safety of elvitegravir / cobicistat / emtricitabine / tenofovir alfa-namide as first-line treatment in naïve patien... | |||||||||||||
Medical condition: AIDS | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001773-26 | Sponsor Protocol Number: 100554 | Start Date*: 2005-05-03 | |||||||||||
Sponsor Name:Bayer HealthCare AG, D-51368 Leverkusen Germany | |||||||||||||
Full Title: A Phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma | |||||||||||||
Medical condition: Advanced hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) BE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000107-28 | Sponsor Protocol Number: 11726 | Start Date*: 2008-04-15 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A Phase II uncontrolled study of BAY 73-4506 (DAST) in previously untreated patients with metastatic or unresectable renal cell cancer (RCC) | |||||||||||||
Medical condition: Renal Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) DE (Completed) FR (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
